TIDMONG
RNS Number : 1369F
Oxford Nutrascience Group PLC
19 April 2011
19 April 2011
Oxford Nutrascience Group plc
("Oxford Nutrascience" or "the Company")
Oxford Nutrascience enters Brazilian pharmaceutical market with
commercial agreement
Oxford Nutrascience the speciality pharmaceutical company using
pharmaceutic and drug delivery science to develop advanced
medicines, has signed an exclusive licensing and distribution
agreement with Ache Laboratorios Farmaceuticos S.A., ("Ache"), one
of Brazil's largest pharmaceutical companies.
Under the terms of the seven year agreement Oxford Nutrascience
will supply Ache with healthcare products which will be sold under
Ache's women's health brand, called 'Inellare'.
It is anticipated that Oxford Nutrascience, using its own
intellectual property, will develop a number of pharmaceutical
products for Ache, as the Brazilian pharmaceutical company expands
its 'Inellare' product range.
Using its extensive physician sales network around Brazil, Ache
will distribute Oxford Nutrascience's products into the fast
growing consumer healthcare market.
This agreement represents a significant progression for Oxford
Nutrascience and it is intended that the relationship with Ache
will provide Oxford Nutrascience with access to the higher value
pharmaceutical industry in Brazil. The Company's strategy is to
increase its focus on developing product innovation for
pharmaceutical companies leveraging advanced pharmaceutic and drug
delivery technology.
Brazil has one of the largest and most dynamic pharmaceutical
markets in the emerging economies, reaching US$22.9 billion in
2010, with 2.06 billion pharmaceutical units (pills, tablets,
medicine doses, among other units used). Source: IMS Health.
Brazil's OTC market is forecast to grow by approximately 5.7%
per annum from 2007 to 2012, making the total size of the market
expected to be US$6.5bn by 2012*
Nigel Theobald, Chief Executive, Oxford Nutrascience Group
Plc
"Working with Ache demonstrates our capability to partner with
major pharmaceutical companies who are seeking product innovation.
The big pharma companies are attracted by our ability to apply
novel pharmaceutic technology to extend the lifecycle of existing
branded generic medicines, which they have often invested many
millions of dollars into.
"Ache has significant commercial infrastructure in Brazil and
the growth of Brazilian pharmaceutical products is making the
country one of the most important global markets for pharmaceutical
companies. Our objective is to target this sector by working
closely with Ache.
"Oxford Nutrascience continues to punch above its weight and it
is encouraging that our other product development and IP, looking
initially into the areas of nonsteroidal anti-inflammatory drugs
continues to attract significant interest from potential commercial
partners.
"We look forward to working with Ache in one of the fastest
growing pharmaceutical markets in Brazil."
Julio Conejero, Managing Director of the OTC & Generics
Business Unit at Ache Laboratorios Farmaceuticos S.A., said:
"Ache has a successful track record of working with innovative
companies and successfully launching their products into the
Brazillian market using our highly trained sales representatives.
We are excited about the prospects of our agreement with Oxford
Nutrascience and their product pipeline.
"We are very pleased to have entered this partnership with
Oxford Nutrascience which gives us access to cutting edge
technology and expertise to develop innovative high quality
products."
- Ends -
* Report on the Brazilian market for vitamins and Calcium
supplements, Brazilian Life Science UK Trade and Investment Team,
Rio de Janeiro.
For further information:
Oxford Nutrascience Group Plc
Nigel Theobald, Chief Executive +44 1865 854874
Mark Way, Investor and Media Relations +44 7786 116991
Ache Laboratorios Farmaceuticos S.A.
Jose Ricardo Mendes da Silva +55 2608 6220
Chief Executive Officer
ZAI Corporate Finance (Nominated Adviser)
John Depasquale +44 20 7060 2220
Sarang Shah +44 20 7060 2220
About Oxford Nutrascience Group Plc
-- Oxford Nutrascience is a speciality pharmaceutical company
that uses novel pharmaceutics and drug delivery science to develop
advanced medicines that extend the lifecycle of branded generics
and soon to be off patent API's.
-- Oxford Nutrascience has developed technology for the use of
prebiotic soluble fibres in medicine delivery systems that disperse
and solubilise medicines, improve taste and mouth feel, simplify
processing and eliminate additives.
-- Development work is currently focused on therapeutic
categories including analgesics, bone health, indigestion and
multivitamin and mineral supplements.
-- Oxford Nutrascience is establishing partnerships with a
number of leading academic centers for pharmaceutics and has a
growing number of technologies to apply to branded generics and
API's.
About Ache Laboratorios Farmaceuticos,S.A.
-- Established 40 years ago, Ache is the largest fully Brazilian
owned pharmaceutical company and currently distributes over 250
brands of prescription and generic drugs and OTC products.
-- During 2009 Ache had sales revenue of over GBP780 million
(R$2,157 million).
-- Ache's sales force makes approximately 30,000 visits to
physicians a year.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRDVLFFFZFBBBL
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Dec 2023 to Dec 2024
